

Medivir's Nomination Committee proposes new Board of Directors ahead of 2016 AGM

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the Nomination Committee's proposal for a new Board of Directors that will be submitted to the 2016 Annual General Meeting. The 2015-2016 Nomination Committee comprises representatives of the company's three largest shareholders at the end of the third quarter of 2015 who have accepted a seat on the Nomination Committee, and the Chairman of the Board. The composition of the 2015-2016 Nomination Committee was as follows:

- Maria Rengefors, Chairman of the Nomination Committee, representing Nordea Fonder
- Anders Hallberg, representing HealthInvest Partners AB
- Bo Öberg, representing the class A shareholders
- Birgitta Stymne Göransson, Chairman of the Board of Medivir AB

The Nomination Committee has agreed, ahead of the upcoming 2016 Annual General Meeting, to propose that a new Board of Directors be appointed by means of the re-election of the Board's existing Members, namely Anders Ekblom, Anders Hallberg, Johan Harmenberg, Helena Levander and Anna Malm Bernsten, and the new election of one Member, namely Thomas Axelsson. The Committee also proposes the election of Anna Malm Bernsten as Chairman of the Board.

Bertil Samuelsson and Birgitta Stymne Göransson have declined re-election.

Thomas Axelsson, born 1959. Thomas has studied industrial engineering at Linköping Technical Institute and is CEO of Vitrolife AB since 2011. He is also a Member of the Board of MedCap AB. Thomas is a former CEO of Stille AB and Artema AB and has worked for a number of companies in the life sciences and medical technology sectors, including as a Business Area Manager at Baxter. He has also been on the Board of several Life science companies including Chairman of the Boards of SBL Vaccin AB, Neovanta Medical AB, Stille AB and Airsonett AB.

For more information please contact:

Maria Rengefors, Nordea Fonder, +46 10-1565 674.

Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 9.00 CET on 3 March 2016.

About Medivir

Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.